Form 8-K - Current report:
SEC Accession No. 0000950170-23-062903
Filing Date
2023-11-13
Accepted
2023-11-13 16:03:09
Documents
14
Period of Report
2023-11-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K alxo-20231113.htm   iXBRL 8-K 58454
2 EX-99.1 alxo-ex99_1.htm EX-99.1 209632
3 GRAPHIC img62044099_0.jpg GRAPHIC 148612
  Complete submission text file 0000950170-23-062903.txt   595391

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT alxo-20231113_pre.xml EX-101.PRE 10574
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT alxo-20231113_lab.xml EX-101.LAB 13613
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT alxo-20231113.xsd EX-101.SCH 2473
8 EXTRACTED XBRL INSTANCE DOCUMENT alxo-20231113_htm.xml XML 4537
Mailing Address 323 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 323 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-466-7125
ALX ONCOLOGY HOLDINGS INC (Filer) CIK: 0001810182 (see all company filings)

IRS No.: 850642577 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39386 | Film No.: 231398499
SIC: 2834 Pharmaceutical Preparations